Efecto del compuesto correlacionado de hexosa activo (AHCC) en patologías inflamatorias intestinalestriquinosis y enfermedad inflamatoria intestinal (EII)

  1. López Cauce, Beatriz
unter der Leitung von:
  1. Juan José García Rodríguez Doktorvater
  2. Marta Puerto Cantero Doktorvater/Doktormutter
  3. Luis Alberto Menchén Viso Doktorvater

Universität der Verteidigung: Universidad Complutense de Madrid

Fecha de defensa: 04 von Juni von 2021

Gericht:
  1. Eduardo Martínez Naves Präsident
  2. Alicia Gómez Barrio Sekretärin
  3. José Antonio Pajares Díaz Vocal
  4. Rosa Maria Del Campo Moreno Vocal
  5. Manuel Barreiro de Acosta Vocal
Fachbereiche:
  1. Medicina

Art: Dissertation

Teseo: 155649 DIALNET lock_openDocta Complutense editor

Zusammenfassung

AHCC is a natural product discovered in 1986 and patented by the Japanese company Amino up, which is obtained from the fermentation of the mycelium of the L. edodes fungus. It is described as a nutraceutical or an immunomodulator due to its ability to modulate the immune response to challenges of different etiology (1). Currently, it is used as concomitant treatment in cancer patients, since it reduces the generalized effects of chemotherapy (2-5).In the present work, we wanted to test the effects of AHCC in an organ where the regulation of the immune system is fundamental: the intestine. To do this, several models were used: the murine model of trichinosis and models of inflammatory bowel disease (IBD), both acute and chronic (6, 7)...